NasdaqGM:ARDXBiotechs
Ardelyx (ARDX): Forecasted 20% Revenue Growth and Profitability Timeline Shape Investor Expectations Ahead of Earnings
Ardelyx (ARDX) remains unprofitable but has managed to shrink its losses by 20% annually over the past five years, with the company now on track to achieve profitability within the next three years. Earnings are projected to surge 69.83% per year, while revenue is forecast to climb 20.1% annually, which is more than double the pace of the wider US market's expected 10.3% growth. With a net profit margin still in negative territory, investors are likely to focus on the positive outlook for...